TESARO Inc (TSRO) is Initiated by RBC Capital Mkts to Outperform, Price Target at $122

TESARO Inc (TSRO) was Initiated by RBC Capital Mkts to “Outperform” and the brokerage firm has set the Price Target at $122. RBC Capital Mkts advised their investors in a research report released on Aug 12, 2016.

Many Wall Street Analysts have commented on TESARO Inc. Company shares were Reiterated by Mizuho on Aug 5, 2016 to “Buy”, Firm has raised the Price Target to $ 100 from a previous price target of $94 .Company shares were Reiterated by Wedbush on Aug 5, 2016 to “Outperform”, Firm has raised the Price Target to $ 107 from a previous price target of $91 .Robert W. Baird Initiated TESARO Inc on Jul 19, 2016 to “Outperform”, Price Target of the shares are set at $105.

On the company’s financial health, TESARO Inc reported $-1.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.42 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.70. The company had revenue of $36.60 million for the quarter, compared to analysts expectations of $2.48 million. During the same quarter in the previous year, the company posted $-1.51 EPS.

TESARO Inc closed down -0.27 points or -0.29% at $93.1 with 8,41,610 shares getting traded on Monday. Post opening the session at $93.29, the shares hit an intraday low of $91.95 and an intraday high of $94.34 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Jul 1, 2016, Jeffrey H. Hanke (Executive VP, R&D and CSO) sold 12,500 shares at $74.02 per share price. According to the SEC, on Jun 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $41.21 per share price. On Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price, according to the Form-4 filing with the securities and exchange commission.

TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.


Leave a Reply

TESARO Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on TESARO Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.